Brain+ AS (OCSE:BRAINP) Research & Development: kr0.00 Mil (TTM As of Jun. 2025)


What is Brain+ AS Research & Development?

Brain+ AS OCSE:BRAINP Research & Development is kr0.00 Mil as of Jun. 2025. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Brain+ AS's Research & Development for the six months ended in Jun. 2025 was kr0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2025 was kr0.00 Mil.

Brain+ AS  (OCSE:BRAINP) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Brain+ AS Research & Development Related Terms

Brain+ AS Research & Development Historical Data

* Premium members only.

The historical data trend for Brain+ AS's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Brain+ AS Research & Development Chart

Brain+ AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Brain+ AS Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Brain+ AS Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of kr0.00 Mil mean?
Brain+ AS (OCSE:BRAINP) has a Research & Development of kr0.00 Mil as of Jun. 2025. Research and development expense is the total cost for research and development activities. View historical data on Brain+ AS and its competitors.
Is Brain+ AS's Research & Development too high?
Brain+ AS's current Research & Development is kr0.00 Mil.
How does Brain+ AS's Research & Development compare to VEEV and BTSG?
Brain+ AS's Research & Development of kr0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Brain+ AS and its competitors. Brain+ AS's current Research & Development is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brain+ AS stock overvalued right now?
Brain+ AS (OCSE:BRAINP) has a current Research & Development of kr0.00 Mil. The current Research & Development is kr0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Brain+ AS (OCSE:BRAINP), the current Research & Development is kr0.00 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Brain+ AS Business Description

Address Svanevej 22, 2nd floor, Copenhagen, DNK, 2400
Brain+ AS is a digital therapeutics company. It is focused on developing and commercializing solutions for dementia care and with a primary focus on Cognitive Stimulation Therapy (CST). The company has developed a set of Digital Medicine technologies. Its product pipeline includes CST Therapist Companion, and CST Home Companion; CST Home Care; CST for Mild Cognitive Impairment (MCI). The company is developing Ayla, a scalable dementia care platform that provides software-based therapy and care solutions designed to support individuals with dementia.